ValuEngine upgraded shares of Conatus Pharmaceuticals (NASDAQ:CNAT) from a hold rating to a buy rating in a report issued on Saturday.
Several other research firms have also recently weighed in on CNAT. Zacks Investment Research upgraded shares of Conatus Pharmaceuticals from a sell rating to a hold rating in a research report on Wednesday, July 4th. Oppenheimer set a $14.00 price objective on shares of Conatus Pharmaceuticals and gave the stock a buy rating in a research report on Thursday, August 2nd. One research analyst has rated the stock with a hold rating and six have assigned a buy rating to the company’s stock. The stock presently has a consensus rating of Buy and an average target price of $12.50.
Conatus Pharmaceuticals stock opened at $6.49 on Friday. The company has a current ratio of 2.35, a quick ratio of 2.35 and a debt-to-equity ratio of 0.68. The company has a market capitalization of $172.13 million, a price-to-earnings ratio of -10.64 and a beta of 1.39. Conatus Pharmaceuticals has a 1 year low of $3.22 and a 1 year high of $7.95.
Hedge funds and other institutional investors have recently bought and sold shares of the business. The Manufacturers Life Insurance Company grew its position in Conatus Pharmaceuticals by 253.0% during the 1st quarter. The Manufacturers Life Insurance Company now owns 22,987 shares of the biotechnology company’s stock worth $135,000 after purchasing an additional 16,476 shares in the last quarter. Jane Street Group LLC purchased a new position in Conatus Pharmaceuticals during the 2nd quarter worth approximately $142,000. MYDA Advisors LLC purchased a new position in Conatus Pharmaceuticals during the 2nd quarter worth approximately $154,000. Wells Fargo & Company MN grew its position in Conatus Pharmaceuticals by 63.4% during the 1st quarter. Wells Fargo & Company MN now owns 55,600 shares of the biotechnology company’s stock worth $326,000 after purchasing an additional 21,564 shares in the last quarter. Finally, LMR Partners LLP purchased a new position in Conatus Pharmaceuticals during the 2nd quarter worth approximately $311,000. Hedge funds and other institutional investors own 33.50% of the company’s stock.
About Conatus Pharmaceuticals
Conatus Pharmaceuticals Inc, a biotechnology company, focuses on the development and commercialization of novel medicines for the treatment of liver diseases in the United States. Its product candidates include Emricasan, an orally active pan-caspase protease inhibitor that is in Phase IIb clinical trials for post-orthotopic liver transplant as a result of hepatitis C virus infection with sustained viral response; for patients with portal hypertension; for patients liver fibrosis caused by nonalcoholic steatohepatitis; and for liver function.
Further Reading: Outstanding Shares and The Effect on Share Price
To view ValuEngine’s full report, visit ValuEngine’s official website.
Receive News & Ratings for Conatus Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Conatus Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.